Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens

Vaccine

Volumn 35, Issue 2, 2017, Pages 361-368

  Maruggi, Giulietta ^a   Chiarot, Emiliano ^a   Giovani, Cinzia ^a   Buccato, Scilla ^a   Bonacci, Stefano ^a   Frigimelica, Elisabetta ^a   Margarit, Immaculada ^a   Geall, Andrew ^b,c   Bensi, Giuliano ^a   Maione, Domenico ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United States)

^c AVID Center   (United States)

Author keywords

GAS; Protective immunity; SAM GBS; Self amplifying mRNA; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; MESSENGER RNA VACCINE; RNA VACCINE; STREPTOLYSIN O; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; MESSENGER RNA; STREPTOCOCCUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GROUP A STREPTOCOCCAL INFECTION; GROUP B STREPTOCOCCAL INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; FEMALE; MICE; RNA, MESSENGER; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES;

EID: 85006983568     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.040     Document Type: Article

References (48)

1. [1] Geall, A.J., Mandl, C.W., Ulmer, J.B., RNA: the new revolution in nucleic acid vaccines. Semin Immunol 25 (2013), 152–159.
2. [2] Deering, R.P., Kommareddy, S., Ulmer, J.B., Brito, L.A., Geall, A.J., Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Del 11 (2014), 885–899.
3. [3] Johansson, D.X., Ljungberg, K., Kakoulidou, M., Liljestrom, P., Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE, 7, 2012, e29732.
4. [4] Liu, M.A., Immunologic basis of vaccine vectors. Immunity 33 (2010), 504–515.
5. [5] Koup, R.A., Douek, D.C., Vaccine design for CD8 T lymphocyte responses. Cold Spring Harbor Perspect Med, 1, 2011, a007252.
6. [6] Liu, M.A., DNA vaccines: an historical perspective and view to the future. Immunol Rev 239 (2011), 62–84.
7. [7] Ferraro, B., Morrow, M.P., Hutnick, N.A., Shin, T.H., Lucke, C.E., Weiner, D.B., Clinical applications of DNA vaccines: current progress. Clin Inf Dis Off Publ Inf Dis Soc Am 53 (2011), 296–302.
8. [8] Kutzler, M.A., Weiner, D.B., DNA vaccines: ready for prime time?. Nat Rev Genet 9 (2008), 776–788.
9. [9] Bagarazzi, M.L., Yan, J., Morrow, M.P., Shen, X., Parker, R.L., Lee, J.C., et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med, 4, 2012, 155ra38.
10. [10] Pascolo, S., Messenger RNA-based vaccines. Expert Opin Biol Ther 4 (2004), 1285–1294.
11. [11] Ulmer, J.B., Mason, P.W., Geall, A., Mandl, C.W., RNA-based vaccines. Vaccine 30 (2012), 4414–4418.
12. [12] Petsch, B., Schnee, M., Vogel, A.B., Lange, E., Hoffmann, B., Voss, D., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30 (2012), 1210–1216.
13. [13] Geall, A.J., Verma, A., Otten, G.R., Shaw, C.A., Hekele, A., Banerjee, K., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109 (2012), 14604–14609.
14. [14] Bogers, W.M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E.J., Davis, D., et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211 (2015), 947–955.
15. [15] Heidenreich, R., Jasny, E., Kowalczyk, A., Lutz, J., Probst, J., Baumhof, P., et al. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer J Int du Cancer 137 (2015), 372–384.
16. [16] Luo, D., Saltzman, W.M., Synthetic DNA delivery systems. Nat Biotechnol 18 (2000), 33–37.
17. [17] Mandl, C.W., Aberle, J.H., Aberle, S.W., Holzmann, H., Allison, S.L., Heinz, F.X., In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 4 (1998), 1438–1440.
18. [18] Brito, L.A., Chan, M., Shaw, C.A., Hekele, A., Carsillo, T., Schaefer, M., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther J Am Soc Gene Ther 22 (2014), 2118–2129.
19. [19] Perri, S., Greer, C.E., Thudium, K., Doe, B., Legg, H., Liu, H., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77 (2003), 10394–10403.
20. [20] Leitner, W.W., Hwang, L.N., deVeer, M.J., Zhou, A., Silverman, R.H., Williams, B.R., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9 (2003), 33–39.
21. [21] Hekele, A., Bertholet, S., Archer, J., Gibson, D.G., Palladino, G., Brito, L.A., et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect, 2, 2013, e52.
22. [22] Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol 19:1 (2015), 332–344.
23. [23] Chiarot, E., Faralla, C., Chiappini, N., Tuscano, G., Falugi, F., Gambellini, G., et al. Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence. mBio, 4, 2013 e00387-12.
24. [24] Nuccitelli, A., Cozzi, R., Gourlay, L.J., Donnarumma, D., Necchi, F., Norais, N., et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci USA 108 (2011), 10278–10283.
25. [25] Gupta, R.K., Siber, G.R., Adjuvants for human vaccines–current status, problems and future prospects. Vaccine 13 (1995), 1263–1276.
26. [26] Ansaldi, F., Canepa, P., Parodi, V., Bacilieri, S., Orsi, A., Compagnino, F., et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 27 (2009), 3345–3348.
27. [27] Guttormsen, H.K., Liu, Y., Paoletti, L.C., Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Hum Vaccines 4 (2008), 370–374.
28. [28] Bensi, G., Mora, M., Tuscano, G., Biagini, M., Chiarot, E., Bombaci, M., et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol Cell Proteom: MCP, 11(M111), 2012, 015693.
29. [29] Maione, D., Margarit, I., Rinaudo, C.D., Masignani, V., Mora, M., Scarselli, M., et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309 (2005), 148–150.
30. [30] Breitling, J., Aebi, M., N-linked protein glycosylation in the endoplasmic reticulum. Cold Spring Harbor Perspect Biol, 5, 2013, a013359.
31. [31] Sierig, G., Cywes, C., Wessels, M.R., Ashbaugh, C.D., Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. Infect Immun 71 (2003), 446–455.
32. [32] Dramsi, S., Caliot, E., Bonne, I., Guadagnini, S., Prevost, M.C., Kojadinovic, M., et al. Assembly and role of pili in group B streptococci. Mol Microbiol 60 (2006), 1401–1413.
33. [33] Pezzicoli, A., Santi, I., Lauer, P., Rosini, R., Rinaudo, D., Grandi, G., et al. Pilus backbone contributes to group B Streptococcus paracellular translocation through epithelial cells. J Infect Dis 198 (2008), 890–898.
34. [34] Chen, V.L., Avci, F.Y., Kasper, D.L., A maternal vaccine against group B Streptococcus: past, present, and future. Vaccine 31:Suppl 4 (2013), D13–D19.
35. [35] Cunningham, M.W., Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13 (2000), 470–511.
36. [36] Pinkney, M., Kapur, V., Smith, J., Weller, U., Palmer, M., Glanville, M., et al. Different forms of streptolysin O produced by Streptococcus pyogenes and by Escherichia coli expressing recombinant toxin: cleavage by streptococcal cysteine protease. Infect Immun 63 (1995), 2776–2779.
37. [37] Avci, F.Y., Kasper, D.L., How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol 28 (2010), 107–130.
38. [38] Manoury, B., Hewitt, E.W., Morrice, N., Dando, P.M., Barrett, A.J., Watts, C., An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396 (1998), 695–699.
39. [39] Baker, C.J., Rench, M.A., Edwards, M.S., Carpenter, R.J., Hays, B.M., Kasper, D.L., Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. New Engl J Med 319 (1988), 1180–1185.
40. [40] Mortensen, R., Nissen, T.N., Blauenfeldt, T., Christensen, J.P., Andersen, P., Dietrich, J., Adaptive immunity against streptococcus pyogenes in adults involves increased IFN-gamma and IgG3 responses compared with children. J Immunol 195 (2015), 1657–1664.
41. [41] Lefeber, D.J., Benaissa-Trouw, B., Vliegenthart, J.F., Kamerling, J.P., Jansen, W.T., Kraaijeveld, K., et al. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun 71 (2003), 6915–6920.
42. [42] Brown, A.F., Murphy, A.G., Lalor, S.J., Leech, J.M., O'Keeffe, K.M., Mac Aogain, M., et al. Memory Th1 cells are protective in invasive staphylococcus aureus infection. PLoS Pathog, 11, 2015, e1005226.
43. [43] Kolata, J.B., Kuhbandner, I., Link, C., Normann, N., Vu, C.H., Steil, L., et al. The fall of a dogma? Unexpected high T-Cell memory response to staphylococcus aureus in humans. J Infect Dis 212 (2015), 830–838.
44. [44] Ulmer, J.B., Mansoura, M.K., Geall, A.J., Vaccines ‘on demand’: science fiction or a future reality. Expert Opin Drug Discov 10 (2015), 101–106.
45. [45] Romero-Steiner, S., Libutti, D., Pais, L.B., Dykes, J., Anderson, P., Whitin, J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4 (1997), 415–422.
46. [46] Margarit, I., Rinaudo, C.D., Galeotti, C.L., Maione, D., Ghezzo, C., Buttazzoni, E., et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 199 (2009), 108–115.
47. [47] Calabro, S., Tortoli, M., Baudner, B.C., Pacitto, A., Cortese, M., O'Hagan, D.T., et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29 (2011), 1812–1823.
48. [48] Fabbrini, M., Sammicheli, C., Margarit, I., Maione, D., Grandi, G., Giuliani, M.M., et al. A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus. J Immunol Methods 378 (2012), 11–19.